Companies › Nanjing Chia-tai Tianqing Pharmaceutical
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine, Hematology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NTQ5082 Factor B (CFB) inhibitor | CFB | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | Jul 2027 |
| NTQ6179 somatostatin receptor subtype 2 (SSTR2) agonist | SSTR2 | Phase 1 | Acromegaly | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07909837 | NTQ6179 | Phase 1 | Acromegaly | Metabolic and endocrine | Apr 2027 |
| NCT06764303 | NTQ5082 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | Hematology | Jul 2027 |
Agios Pharmaceuticals Marea Therapeutics Biomea Fusion Jiangsu BioJeTay Biotechnology JCR Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.